Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Warner Biddle
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 149
- Beta
- 1.99
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -0.28
Financials
Revenue
$0.00-100.0%Net Income
$-38.32MEBITDA
$-37.21MFree Cash Flow
$-40.60MEPS (diluted)
$-0.63Shares Outstanding (diluted)
60.90M+41.2%Operating Expenses
$39.56MCash & Debt
$199.43MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-161.31M | $-3.64 |
| 2024 | $0.00 | $-127.48M | $-3.33 |
| 2023 | $0.00 | $-60.37M | $-0.00 |
| 2022 | $7.03M | $-28.89M | $-1.12 |
| 2021 | $5.66M | $-26.35M | $-1.02 |
Valuation
KYTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
163+225.00%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·11d ago·Positive
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
View source ↗ - Newsglobenewswire.com·12d ago·Positive
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel's differentiated construct
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Kyverna Therapeutics to Present at Upcoming Investor Conferences EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences:
View source ↗ - Newsseekingalpha.com·54d ago·Neutral
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval Kyverna Therapeutics, Inc. remains a compelling Buy as it advances mivocabtagene autoleucel for autoimmune diseases, targeting first approval in stiff person syndrome. Updated KYSA-8 trial data show all 26 patients remained off chronic immunotherapies at 16 weeks, with 81% mobility improvement, supporting regulatory momentum. Rolling BLA submission for miv-cel is underway, with anticipated completion in late 2026 and potentia
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy's potential across neuroimmunology
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.68 per share
Typical surprise +7.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.63 vs $-0.68beat
- Tue, May 12$-0.66 vs $-0.75beat
- Thu, Mar 26$-0.80 vs $-0.84beat
- Wed, Nov 12$-0.85 vs $-0.97beat
- Tue, Aug 12$-0.97 vs $-1.00beat
- Tue, May 13$-1.03 vs $-1.21beat
Estimates and results for KYTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KYTX officers and directors.
- Bought
- $47.4m
- Sold
- $293k
7 trades
1 trade
- Seidenberg Beth Cbought
- Westlake Biopartners Opportunity Fund I, L.p.bought
- Walker Karen Mariesold
- Vida Ventures, Llcbought
- Vida Ventures, Llcbought
- Bain Capital Life Sciences Investors, Llcbought
- Gilead Sciences, Inc.bought
- Northpond Ventures Iii Gp, Llcbought
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in KYTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.